Cargando…

Noninfectious Intermediate, Posterior, or Panuveitis: Results from the Retrospective, Observational, International EyeCOPE Study

INTRODUCTION: The EyeCOPE study characterized noninfectious intermediate posterior, or panuveitis (NIIPPU) before biologic agents were widely available. METHODS: This retrospective, observational study included adults with NIIPPU attending a routine ophthalmological visit. Data were collected from t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kramer, Michal, Brichova, Michaela, Tugal-Tutkun, Ilknur, Panchenko, Mykola, Gormezano, Natali, Koenigsbauer, Franziska, Franco, Pablo, Muccioli, Cristina, Hasanreisoglu, Murat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319263/
https://www.ncbi.nlm.nih.gov/pubmed/34117983
http://dx.doi.org/10.1007/s40123-021-00351-4
Descripción
Sumario:INTRODUCTION: The EyeCOPE study characterized noninfectious intermediate posterior, or panuveitis (NIIPPU) before biologic agents were widely available. METHODS: This retrospective, observational study included adults with NIIPPU attending a routine ophthalmological visit. Data were collected from the study visit and medical records. RESULTS: Of 565 patients, 58.8% were female, and the mean age was 41.3 years; 33.8% had idiopathic uveitis and 45.8% had panuveitis. The median time from symptom onset to diagnosis and treatment was 27.0 and 30.5 days, respectively. Patients received immunosuppressants and systemic/local corticosteroids. Most patients experienced substantial decline in ocular function (mean best corrected visual acuity, 0.4 logMAR). Mean total work productivity impairment among employed patients was 31.0%. Most patients reported ocular complications (70.8%) such as vision loss and cataracts. CONCLUSIONS: Despite treatment, most patients with NIIPPU experienced a decline in ocular function and ocular complications. There is an unmet need for additional NIIPPU treatment, such as targeted monoclonal antibodies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40123-021-00351-4.